Gilead Sciences Inc (GILD)

63.30
+0.55(+0.88%)
  • Volume:
    5,479
  • Bid/Ask:
    62.63/63.30
  • Day's Range:
    62.21 - 63.31
  • Type:Equity
  • Market:Germany
  • ISIN:US3755581036
  • WKN:885823

GILD Overview

Prev. Close
62.75
Day's Range
62.21-63.31
Revenue
-
Open
62.28
52 wk Range
50.8-65.2
EPS
-
Volume
5,479
Market Cap
78.95B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
10,954
P/E Ratio
-
Beta
-
1-Year Change
19.77%
Shares Outstanding
1,254,383,522
Next Earnings Date
-
What is your sentiment on Gilead Sciences Inc?
or
Vote to see community's results!

Gilead Sciences Inc Company Profile

Employees
13600

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Read More

Type
Daily
Weekly
Monthly
Moving AveragesStrong BuyBuyStrong Buy
Technical IndicatorsSellStrong BuyStrong Buy
SummaryNeutralStrong BuyStrong Buy
  • Good job GILD. bullish move forward
    0
    • Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
      0
      • Up Again
        0
        • Time to load up before the big rise coming next week
          3
          • Classic pump n’ dump. What a shambles
            1
            • Will reach above 95
              5
              • Good time to accumulate.
                1
                • Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
                  2
                  • High chance to be trading above 90, good long stock
                    4
                    • By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
                      3
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.